JAMES SMITH

Chief Executive Officer

James Smith founded Co-Pharma , an infectious disease consultancy in 2017 , after working 40 years in the pharmaceutical industry for companies such as CIBA-Geigy , Lundbeck and Hoffmann La Roche in Switzerland and Contract Research Organizations (CROs) . At Hoffmann La-Roche he worked on infectious disease projects covering antimalarials, antibiotics and the influenza antivirals Tamiflu and Xofluza. During the 2009 influenza pandemic he was the Medical representative on the Roche Pandemic Taskforce , and had interactions with infectious disease experts, public health institutions WHO ,CDC and ECDC and regulatory authorities, FDA and EMA. He has presented on influenza topics at multiple international scientific meetings. He was co-founder of a contract research organization (CRO) based in UK, Germany and Switzerland & took the role of Research Director, offering clinical trial services to pharmaceutical companies from phase I to III. Over a period of 10 years with CROs,he gained broad experience in the conduct of clinical trials in various therapeutic areas , design of studies and evaluation of their results. He is the author of more than 30 scientific publications.
James received a PhD in 1983 from London University in pharmacology and the Swiss Diploma for Pharmaceutical Professionals in 2002